Moneycontrol PRO
HomeNewsBusinessCompaniesLupin actively eyeing buys in Latin America

Lupin actively eyeing buys in Latin America

Lupin is actively evaluating acquisition opportunities in Latin America, its managing director said on Thursday.

January 28, 2011 / 14:17 IST
     
     
    26 Aug, 2025 12:21
    Volume
    Todays L/H
    More

    Lupin is actively evaluating acquisition opportunities in Latin America, its managing director said on Thursday.


    "Latin America is an interesting market because of the size itself but it's a highly competed market," Kamal Sharma told Reuters in a telephone interview.


    "We are actively evaluating a few things," he said, but refused to give a timeframe for the deals.


    "In the three major geographies, besides the others, like Mexico, Brazil and Argentina, there is a large local industry... plus all the multi-nationals are present... keeping that in mind, we have to be strategically right," he said.


    Earlier in the day, Lupin reported a forecast-beating 39.13% rise in consolidated quarterly net profit to Rs 224 crore on net sales of Rs 1,467 crore.



    Oral contraceptives biz to start


    Lupin, which has made 26 filings in the oral contraceptives segment so far, expects four US FDA approvals from September onwards, Sharma said.


    "We were expecting the approvals to come from April-May but there has been a general delay of about three months by the authorities," he said.


    The drugmaker, which stands as the fifth largest generics player in the US market, has set up a dedicated oral contraceptive making facility in central Indian town of Indore.


    "We see the facility going on stream from start of April," he said adding, it would remain idle till the approvals start coming.


    The revenue from the facility would depend on factors like pace of products approvals, progress of market share and price erosion in the US market, he said.


    "The OC (oral contraceptives) market in the US is about USD 4.5 billion and there has been lesser erosion in prices so far," he said.


    Earlier this month, Lupin signed a strategic agreement with Brazil's state-run Farmanguinhos to supply four-in-one tuberculosis drug for five years.


    "To begin with, we would be participating in a tender which comes out every year...Initially, it would be for supply of goods to the Brazilian partner," he said. "... at a later date, we will think about the manufacturing unit."

    Shares of Lupin closed at Rs 442.85 on Thursday, down 5.25% in a weak Mumbai market.

    first published: Jan 28, 2011 08:17 am

    Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

    Subscribe to Tech Newsletters

    • On Saturdays

      Find the best of Al News in one place, specially curated for you every weekend.

    • Daily-Weekdays

      Stay on top of the latest tech trends and biggest startup news.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347